Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001351120 | SCV001545560 | uncertain significance | not provided | 2023-12-22 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 213 of the INPPL1 protein (p.Thr213Ala). This variant is present in population databases (rs138340411, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with INPPL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1046549). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV001351120 | SCV004137228 | uncertain significance | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004036644 | SCV004885677 | uncertain significance | Inborn genetic diseases | 2021-07-15 | criteria provided, single submitter | clinical testing | The c.637A>G (p.T213A) alteration is located in exon 5 (coding exon 5) of the INPPL1 gene. This alteration results from a A to G substitution at nucleotide position 637, causing the threonine (T) at amino acid position 213 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |